...
首页> 外文期刊>Cureus. >Subconjunctival Ab Externo Gel Stent Implantation for Refractory Glaucoma After High-Risk Penetrating Keratoplasty
【24h】

Subconjunctival Ab Externo Gel Stent Implantation for Refractory Glaucoma After High-Risk Penetrating Keratoplasty

机译:在高危渗透角膜术后难治性青光眼的沉积物Ab外部凝胶支架植入

获取原文
   

获取外文期刊封面封底 >>

       

摘要

This case study reports the successful deployment of the XEN45 gel stent (AbbVie Inc, Chicago, IL) through an ab externo approach in a 73-year-old woman with refractory glaucoma following high-risk penetrating keratoplasty (PK) 10 years prior. The PK was for corneal perforation secondary to peripheral ulcerative keratitis, which required systemic immunosuppression comprising intravenous cyclophosphamide, azathioprine, and corticosteroids to stabilise the disease and prevent corneal graft rejection. The patient’s intraocular pressure was reduced from 40 mmHg preoperatively to 12 mmHg six months after surgery, off medication. The patient’s visual acuity and visual fields remained stable. The XEN45 gel stent utilising the ab externo approach can be considered as a potential tool to lower intraocular pressure in patients with glaucoma after corneal keratoplasty.
机译:本案例研究报告,在高危渗透角膜术(PK)之前,在一名73岁的女性中,通过AB外部方法成功地部署了Xen45凝胶支架(Abbvie Inc,Chicago,IL)通过难治性青光眼的难治性青光眼。 PK是用于外周溃疡性角膜炎的角膜穿孔,其要求包含静脉内环磷酰胺,偶氮嘌呤和皮质类固醇的全身免疫抑制,以稳定疾病并防止角膜移植物排斥。患者的眼内压力从手术后六个月术前从40mmHg减少到12mmHg,脱掉药物。患者的视力和视觉领域保持稳定。利用AB外部方法的Xen45凝胶支架可以被认为是角膜插孔后青光眼患者患者眼内压力的潜在工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号